Scarica l'app Stockscreener
98.05
1.48%
-1.47
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$99.52
Aprire:
$98.83
Volume 24 ore:
22.42M
Relative Volume:
2.15
Capitalizzazione di mercato:
$248.03B
Reddito:
$63.17B
Utile/perdita netta:
$12.15B
Rapporto P/E:
54.47
EPS:
1.8
Flusso di cassa netto:
$14.84B
1 W Prestazione:
-3.87%
1M Prestazione:
+0.63%
6M Prestazione:
-24.38%
1 anno Prestazione:
-6.94%
Intervallo 1D:
$97.90
$99.68
Intervallo di 1 settimana:
$97.82
$102.28
Portata 52W:
$94.48
$134.63
Merck Co Inc Stock (MRK) Company Profile
Nome
Merck Co Inc
Settore
Industria
Telefono
908-740-4000
Indirizzo
2000 GALLOPING HILL ROAD, KENILWORTH, NJ
Confronta MRK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-12-04 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-11 | Downgrade | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-03-11 | Downgrade | Societe Generale | Hold → Sell |
| 2024-01-04 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Buy |
| 2023-10-27 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Hold |
| 2023-04-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-03-28 | Downgrade | Societe Generale | Buy → Hold |
| 2023-03-13 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Iniziato | Jefferies | Buy |
| 2023-02-22 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-10-10 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-14 | Aggiornamento | Berenberg | Hold → Buy |
| 2022-07-06 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Ripresa | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-16 | Iniziato | Daiwa Securities | Neutral |
| 2021-12-13 | Downgrade | UBS | Buy → Neutral |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-12-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-29 | Downgrade | Citigroup | Buy → Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-01 | Aggiornamento | Argus | Hold → Buy |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-20 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-08-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-06-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-16 | Iniziato | SVB Leerink | Outperform |
| 2019-07-03 | Iniziato | Mizuho | Buy |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-05-13 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Reiterato | Citigroup | Buy |
| 2018-10-09 | Ripresa | Guggenheim | Buy |
| 2018-04-23 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-04-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-07 | Reiterato | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Merck Co Inc Borsa (MRK) Ultime notizie
Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck? - The Motley Fool
Merck - Contract Pharma
Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows - AOL
Merck & Co., Inc. (NYSE:MRK) Trading Down 0.8%Time to Sell? - MarketBeat
Merck: LM-299 antibody agreement finalized - Marketscreener.com
BMO cuts rating on Merck and Biogen, on lack of near term catalyst - Investing.com
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
BMO Capital Markets Downgrades Merck & Co., Inc. (NYSE:MRK) to Market Perform - MarketBeat
Merck’s doravirine/islatravir combo yields positive results in Phase 3 HIV-1 trials - World Pharmaceutical Frontiers
Merck secures global rights to novel cancer therapy - Investing.com
Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now? - Insider Monkey
Merck & Co buoyed by Phase III results with HIV tablet - The Pharma Letter
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet - Simply Wall St
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody - Business Wire
Analyst recommendations: Fedex, Merck, Nike, Coinbase, Tesla... - Marketscreener.com
Merck stock downgraded by BMO amid Gardasil, Keytruda concerns - Investing.com
Merck & Co Inc (MRK) DCF Valuation: Is The Stock Undervalued? - The Acquirer's Multiple
Merck & Co. Inc. stock outperforms competitors on strong trading day - MarketWatch
Merck & Co., Inc. (NYSE:MRK) Shares Up 0.5%What's Next? - MarketBeat
Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials - Benzinga
Merck & Co (MRK) technical analysisMerck & Co (NYSE:MRK), Hansoh Pharmaceutical Gr (OTC:HNSPF) - Benzinga
Merck: encouraging phase III results in HIV - Marketscreener.com
Merck's HIV treatment meets main goal in two late-stage studies - Reuters
Merck Buys $50 Million of Personalis Stock - Marketscreener.com
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna - Yahoo Finance
Merck shares reaffirm Market Perform rating on global in-licensing - Investing.com
Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time - Seeking Alpha
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug - Yahoo Finance
Merck’s RSV antibody could soon paddle into the rough waters of a crowded market - PharmaVoice
Merck's HIV-1 treatment meets efficacy in Phase 3 trials - Investing.com
Merck's HIV treatment meets main goal of two late-stage studies - Marketscreener.com
Merck stock slips after trial data for HIV drug (MRK:NYSE) - Seeking Alpha
Merck gets rights to Hansoh Pharma’s investigational diabetes drug - World Pharmaceutical Frontiers
Merck (MRK) Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir - StreetInsider.com
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection - Marketscreener.com
Why Is Merck & Co., Inc. (MRK) Among the Best Dividend Stocks to Invest In? - Yahoo Finance
Merck snags Chinese obesity drug in nearly $2 billion deal - Fortune
Merck (MRK) Stock Moves -1.72%: What You Should Know - Yahoo Finance
Merck strikes a $2B GLP-1 deal with Hansoh - BioWorld Online
Deal Watch: Merck Decides Better Late Than Never In GLP-1 Deal With Hansoh - Citeline News & Insights
Merck & Co. Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Merck & Co., Inc. (NYSE:MRK) Trading Up 0.4%Still a Buy? - MarketBeat
Merck reaches weight-loss drug deal worth up to $2 billion with China-based Hansoh - Yahoo Finance
Merck & Co. taps Chinese biotech for entry into oral GLP-1 arena - FirstWord Pharma
Merck & Co buys in oral GLP-1 RA from China’s Hansoh - The Pharma Letter
Spotlight On: Merck enters the obesity game — four key takeaways - FirstWord Pharma
What's Going On With Viking Therapeutics Stock On Wednesday? - Yahoo Finance
Merck Acquires Potential Weight Loss Drug for $2 Billion - GuruFocus.com
Merck moves into obesity with deal for Hansoh’s GLP-1 pill - BioPharma Dive
Merck in global license agreement with Hansoh Pharma for weight-loss drug - ShareCast
Elon Musk, Netflix fined, Merck's GLP-1 deal: Market Minute - Yahoo Finance
Merck Co Inc Azioni (MRK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):